The London School of Hygiene & Tropical Medicine is to lead a major new clinical trial in Southern and East Africa which aims to tackle the high number of deaths caused by HIV-associated cryptococcal meningitis (CM), a severe fungal infection of the brain that occurs in patients with advanced HIV infection.
AMBITION hopes to identify a new very clinically-effective and cost-effective treatment for CM using very high single doses of the drug Liposomal Amphotericin B (Ambisome). The project will recruit 850 patients across six African sites, making it the largest ever CM trial. Recruitment will commence in late 2017.
Head Shot of Joe Jarvis
Dr. Joe Jarvis
Joe Jarvis, Associate Professor from the London School of Hygiene & Tropical Medicine and Research Associate at the Botswana Harvard AIDS Institute Partnership is AMBITION’s Chief Investigator. He said: “Cryptococcal meningitis is a leading cause of death in HIV-infected individuals in Africa. Current drugs used to treat it are either ineffective or cost too much to administer. There is an urgent need to find novel treatments that can be safely given in low resource settings where the majority of cryptococcal meningitis cases occur. Being able to effectively treat this severe infection with a single high dose of liposomal amphotericin would revolutionise the management of late stage HIV-infection in Africa, and has the potential to save many thousands of lives every year.” Read more . . .
This entry was posted in BHP in the News and tagged cryptococcal meningitis, HIV, Joe Jarvis on October 30, 2017 by Martha Henry.